EUVIMEDEUVIMED entdecken
Crossref

Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer

Ki Tae Kim, Min Hee Lee, Su-Jin Shin, In Cho, Jung Cheol Kuk, Jina Yun, Yoon Young Choi iD

Gastric Cancer · 2025-01 · 28 (1) · 12-26

DOI: 10.1007/s10120-024-01567-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 09.11.2024. Verfasst von Ki Tae Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics & Dental Pharmacology, School of Dentistry, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cancer-Associated Fibroblasts, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gastric cancer (GC) remains a significant cause of cancer-related mortality worldwide. Despite the transformative impact of immune checkpoint blockade (ICB) therapies across various cancers, only a minority of patients with metastatic GC (mGC) benefit, emphasizing the urgent need for precise biomarkers to predict therapeutic responses and optimize patient selection. METHODS: In this multi-omics study, we conducted whole exome and transcriptome sequencing on 12 tumors from mGC patients treated with nivolumab as first-line therapy. To validate our findings, we performed whole transcriptome sequencing on 17 additional tumors and analyzed 45 tumors from public dataset (PRJEB25780) of patients who received ICB therapy as second or third-line treatment. Comprehensive multi-omics analyses were conducted using single-cell RNA sequencing (n = 5, GSE167297) and spatial transcriptome sequencing (n = 2, independent internal dataset). RESULTS: ICB-sensitive tumors exhibited robust activation of the interferon response pathway, while ICB-resistant tumors displayed epithelial-mesenchymal transition signatures. Intriguingly, at the single-cell level, genes associated with ICB sensitivity were predominantly expressed in immune cells, whereas genes associated with resistance were primarily found in cancer-associated fibroblasts (CAFs), particularly the desmoplastic CAF (dCAF) subtype. We identified DCN as a hallmark dCAF marker, and high DCN expression was inversely correlated with PD-L1 levels, ICB resistance, and poor prognosis in mGC (log-rank p = 0.027). CONCLUSION: This study elucidates the critical influence of the tumor microenvironment, specifically dCAFs, in mediating ICB resistance in mGC. Our findings highlight DCN as a representative marker for dCAF and a promising negative predictive biomarker for ICB response. These findings highlight the complex stromal-immune interactions and open avenues for personalized treatment for mGC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsCancer-Associated FibroblastsImmune Checkpoint InhibitorsDrug Resistance, NeoplasmBiomarkers, TumorHumansTumor MicroenvironmentFemaleMaleEpithelial-Mesenchymal TransitionNivolumabPrognosisGene Expression Regulation, NeoplasticExome Sequencing

Stichwörter der Autor:innen

BiomarkerCancer-associated fibroblastGastric cancerImmune checkpoint blockadeMulti-omics

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorNivolumab

Autor:innen und Institutionen

  • Department of Molecular Genetics & Dental Pharmacology, School of Dentistry, Seoul National University, Seoul, Korea.
  • Dental Research Institute and Dental Multi-omics Center, Seoul National University, Seoul, South Korea.
  • Department of Radiology, Soonchunhyang Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • Department of Pathology, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Surgery, Soonchunhyang Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do, Republic of Korea.
  • Department of Medicine, Division of Hematology/Oncology, Soonchunhyang Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

ORCID-Profile: Yoon Young Choi

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Kim, K. T., Lee, M. H., Shin, S. J., Cho, I., Kuk, J. C., Yun, J., & Choi, Y. Y. (2025). Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer. Gastric Cancer, 28(1), 12-26. https://doi.org/10.1007/s10120-024-01567-6

Vancouver

Kim KT, Lee MH, Shin SJ, Cho I, Kuk JC, Yun J, et al. Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer. Gastric Cancer. 2025;28(1):12-26. doi:10.1007/s10120-024-01567-6

BibTeX
@article{Kim2025,
  author = {Kim, Ki Tae and Lee, Min Hee and Shin, Su-Jin and Cho, In and Kuk, Jung Cheol and Yun, Jina and Choi, Yoon Young},
  title = {Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer},
  journal = {Gastric Cancer},
  year = {2025},
  volume = {28},
  number = {1},
  pages = {12--26},
  doi = {10.1007/s10120-024-01567-6}
}
Kostenlos starten →